NCT03939871: A Study of Fulvestrant Combined With Oral Vinorelbine in Hormone Receptor-positive Advanced Breast Cancer

NCT03939871
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Endocrine (Hormone) Therapy, Chemotherapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 70 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must be chemotherapy naïve in the metastatic setting or had one prior regimen for metastatic breast cancer
Exclusions: Patients with symptomatic brain metastases
https://ClinicalTrials.gov/show/NCT03939871

Comments are closed.

Up ↑